Biotronik commences heart failure technology trial

Biotronik has commenced a new clinical trial called BIO.Detect HF II, which aims to assess the benefits of its latest technology for cardiac resynchronisation therapy (CRT) optimisation.

The trial will evaluate the clinical relevance of the company's innovative intracardiac impedance (ICI) sensing technology and its ability to assess haemodynamic parameters among heart failure patients.

ICI technology is incorporated into Biotronik's newest CRT defibrillators, including the cutting-edge Lumax 740 HF-T, and is used to judge changes in impedance during the cycle of the heart.

Because these systems are built into the devices and work with traditional leads, patients need not undergo any further complex or time-consuming invasive procedures.

Christoph Bohmer, international president for Biotronik, said: "Our ICI feature is just one of the innovations Biotronik has recently developed to broaden the range of options physicians have for diagnosis and therapy – and offer patients the best care possible."

Earlier this month, the company reported positive data from 4Ever, a new clinical study assessing the benefits of its Pulsar self-expanding stent system.